CSBR — CHAMPIONS ONCOLOGY, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 771856 ·
Last close
$4.98
Market Cap
$69.31M
52W High
$8.31
52W Low
$4.59
ADV30
12,924
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jul 2026 | — | — | — | — | — | — | — |
| Apr 2026 | 13,835,000 | 7,025,000 | -521,000 | -667,000 | 26,989,000 | 4,872,000 | 22,921,000 |
| Jan 2026 | 16,559,000 | 7,725,000 | -187,000 | -279,000 | 28,447,000 | 7,127,000 | 24,069,000 |
| Oct 2025 | 15,035,000 | 7,773,000 | 185,000 | 299,000 | 30,162,000 | 8,516,000 | 25,931,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-4,472,000
Investing CF
$-540,000
Financing CF
$99,000
CapEx
$-564,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.06
As of
2026-09-13
Balance + Analyst (yfinance extras)
Retained Earnings
$-81,067,000
Inventory
—
Receivables
$13,178,000
ST Investments
—
EBIT TTM
$-1,030,000
Pretax Income TTM
$-929,000
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$59,425,000
EBITDA
$348,000
Free Cash Flow
$-4,291,125
Enterprise Value
$70,649,680
Total Cash
$4,872,000
Total Debt
$4,598,000
Shares Out
13,918,569
Trailing EPS
$-0.08
Book Value
$0.28
ROE
-30.0%
ROA
-2.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Apr 2026 | 59,425,000 | -1,029,000 | -1,175,000 | 26,989,000 | 22,921,000 | 3,939,000 | -4,472,000 |
| Apr 2025 | 56,944,000 | 4,846,000 | 4,701,000 | 32,344,000 | 28,572,000 | 3,772,000 | 7,386,000 |
| Apr 2024 | 50,155,000 | -6,921,000 | -7,276,000 | 26,132,000 | 28,035,000 | -1,903,000 | -6,137,000 |
| Apr 2023 | 53,870,000 | -4,449,000 | -5,335,000 | 34,311,000 | 29,675,000 | 4,636,000 | 3,972,000 |
TTM Snapshot
Revenues TTM
$57,944,000
NetIncome TTM
$-2,282,000
OpCashFlow TTM
—
Assets (Latest)
$28,447,000
Forward EPS
$0.10
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OKYO | OKYO Pharma Ltd | $72.95M | $1.39 | — |
| PTHS | Pelthos Therapeutics Inc. | $78.48M | $20.50 | — |
| KLRS | Kalaris Therapeutics, Inc. | $59.51M | $2.50 | — |
| CRDF | Cardiff Oncology, Inc. | $82.46M | $1.06 | — |
| VISK | Viskase Holdings, Inc. | $58.19M | $4.06 | — |
News headlines (Yahoo Finance, 1h cache)
Capitalize on the Global PDX Models Shift: Benchmark Charles River, Crown Bioscience, Champions Oncology, The Jackson Laboratory and Oncodesign to Secure Precision Oncology ROI
2026-09-22 08:29 · Yahoo
CSBR Stock Slips Post Q1 Earnings Despite Revenue, Margin Growth
2026-09-15 15:12 · Yahoo
Champions Oncology Inc (CSBR) (Q1 2027) Earnings Call Highlights: Data Licensing Surge and ...
2026-09-15 01:00 · Yahoo
Champions Oncology (CSBR) Q1 2027 Earnings Call Transcript
2026-09-11 13:58 · Yahoo
Champions Oncology, Inc. Q1 2027 Earnings Call Summary
2026-09-11 12:30 · Yahoo
Champions Oncology Q1 Earnings Call Highlights
2026-09-10 21:02 · Yahoo
Champions Oncology to Announce First Quarter Financial Results on Thursday, September 10, 2026
2026-09-04 15:15 · Yahoo
Champions Oncology Inc (CSBR) (Q4 2026) Earnings Call Highlights: Record Revenue and Positive ...
2026-07-30 03:00 · Yahoo
Champions Oncology Reports Record Annual Revenue of $59 Million
2026-07-27 20:00 · Yahoo
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 27, 2026
2026-07-20 20:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.